Mirion Technologies Inc Stock Price, News & Analysis

Mirion (NYSE: MIR) reported Q3 2024 results with revenues increasing 8.2% to $206.8 million. Despite a net loss of $14.0 million, the company showed improved operational performance with Adjusted EBITDA rising 17.8% to $45.7 million and margin expanding to 22.1%. Adjusted EPS reached $0.08, up from $0.05 year-over-year.

The company updated its FY2024 guidance, raising revenue growth expectations to 6-7% and organic growth to 5-6%. Mirion maintains its Adjusted EBITDA target of $195-205 million and Adjusted EPS of $0.37-0.42, while tightening its adjusted free cash flow range to $65-75 million.

Mirion Technologies (NYSE: MIR) has secured two major contracts for the Sizewell C nuclear power station project in the UK. The first contract, awarded in October 2024, covers Electrical Penetration Systems (EPS) for secure cable passage through reactor containment walls. The second contract, from May 2024, is for Boron Meter Systems to measure boron concentration in water. The 3.2-gigawatt Sizewell C facility will mirror Hinkley Point C's design and generate low-carbon electricity for approximately 6 million homes.

Mirion Technologies (NYSE: MIR) has announced its upcoming Investor Day scheduled for December 3, 2024, at 2:00 p.m. ET at the New York Stock Exchange. The event will feature presentations from key leadership, including CEO Thomas Logan on radiation safety strategy, CFO Brian Schopfer on financial outlook, Technologies Group President Loic Eloy on nuclear innovations, and Medical Group EVP Luis Rivera on cancer care developments.

The event will be webcast live, with in-person attendance to invited institutional investors and financial analysts who must register by November 18, 2024. Interested parties can access the webcast through the company's IR website or via a dedicated registration link.

Mirion Technologies (NYSE: MIR) has announced its schedule for the release of third quarter 2024 financial results. The company will disclose its earnings after the market closes on Tuesday, October 29, 2024. Following this, Mirion will host a conference call on Wednesday, October 30, 2024, at 11:00 am ET to discuss the results in detail.

Interested parties can join the call by dialing 1-877-407-9208 (US) or 1-201-493-6784 (international). A live webcast will be available on the company's investor relations website. For those unable to attend, a telephonic replay will be accessible until November 13, 2024, using the access code 13749095.

Varian, a Siemens Healthineers company, and Sun Nuclear, a Mirion Medical company (NYSE: MIR), have announced an alliance to expand Varian's quality assurance (QA) offerings for radiotherapy solutions. Under the agreement, Varian will sell Sun Nuclear's SunCHECK® quality management platform across its sales channels, broadening QA support for its treatment delivery solutions.

Sun Nuclear, a market leader in radiation oncology quality management, has solutions used in over 6,000 cancer treatment facilities. The alliance aims to enhance clinical workflows, improve treatment outcomes, and ease radiation therapy technology adoption. Varian will continue to support existing QA customers while expanding its comprehensive QA offerings.

As part of the agreement, Varian and Sun Nuclear will also enhance the integration of QA software for future radiotherapy offerings, reinforcing Varian's commitment to excellence in patient care and safety.

Mirion (NYSE: MIR) reported Q2 2024 financial results with revenues increasing 5.0% to $207.1 million. The company saw a net loss of $12.0 million, an improvement from $28.4 million loss in Q2 2023. Adjusted EBITDA rose 10.2% to $48.8 million, with margin expanding to 23.6%. Mirion raised its full-year adjusted EBITDA guidance to $195-$205 million while reiterating 5-7% revenue growth and $0.37-$0.42 adjusted EPS guidance. The company also announced a strategic nuclear new build partnership with EDF, strengthening its position in the nuclear market.

Mirion Technologies (NYSE: MIR) has announced its schedule for the release of second quarter 2024 financial results. The company will disclose its earnings after market close on Thursday, August 1, 2024, followed by a conference call on Friday, August 2, 2024, at 11:00 am ET to discuss the results.

Investors and analysts can participate in the call by dialing 1-877-407-9208 (US) or 1-201-493-6784 (international). A live webcast will be available on the company's investor relations website. For those unable to attend, a telephonic replay will be accessible until August 16, 2024, using the access code 13747541.

Mirion (NYSE: MIR) has announced a change in timing for its management team's presentation at the Jefferies’ 2024 Global Healthcare Conference. The presentation will now start at 3:30 PM ET on Thursday, June 6, 2024. The event will be webcast live on Mirion's investor relations website under the 'Events and Presentations' section. An archived version of the webcast will be accessible within twelve hours after the event concludes.

Mirion (NYSE: MIR), a global radiation detection and monitoring solutions provider, announced the completion of the redemption of its outstanding publicly traded warrants. As of May 20, 2024, Mirion redeemed the warrants at $0.10 each. Of the 18,749,779 warrants, 2,131 were exercised for cash, and 18,074,285 were exercised on a cashless basis, resulting in a total of 3,978,418 new common shares issued. The remaining 673,363 unexercised warrants were redeemed for $67,336.30. The public warrants ceased trading on the NYSE before the market opened on May 20, 2024. The private placement warrants remain unaffected and continue to be outstanding. The common shares continue to trade under the symbol 'MIR'. Additional details are available on Mirion’s Investor Relations website.